Portfolio

portfolio

BioSilta Oy

BioSilta is a spin-out company from the Bioprocess Engineering Laboratory of the University of Oulu, Finland. The company has developed a break-through growth-media technology EnBase™ for the production of biologics. EnBase™ enables controlled growth of bacteria cells providing 10 to 100 times higher yields in small scale (from shake flask down to micro titer plate) production.


www.biosilta.com

 

Oy Lx Therapies Ltd

Lx Therapies, a spin-out company from Ark Therapeutics Group plc, is a drug development company focused on developing gene-mediated therapies (VEGF-C/D) for the prevention and treatment of diseases of lymphatic vasculature. The initial focus of the company is on breast cancer-related lymphedema, a relatively common complication of breast cancer treatment for which there is no cure or effective treatment today.

 

portfolio

Priaxon AG

Priaxon, based in Munich, Germany, is a drug development company focused on small molecule therapeutics inhibiting protein-protein interactions. The company employs a unique combination of proprietary chemoinformatic tools and innovative synthetic chemistry to rationalize and accelerate the drug discovery process. Priaxon's lead projects include an inhibitor of the Mdm2-p53 interaction and a multi-action antibiotic compund. 


www.priaxon.com

 

portfolio

Medtentia International Ltd Oy

Medtentia is a Finnish medtech company developing novel mitral valve repair products based on the company’s proprietary helix concept. Medtentia’s mitral valve repair products, including a novel annuloplasty ring, have the potential to significantly reduce the invasiveness, operation time and morbidity currently associated with mitral valve repair and replacement operations.

www.medtentia.com

 

portfolio

Medeia Therapeutics Oy

Medeia Therapeutics Oy is a drug discovery company focused on novel therapeutics for neurodegenerative diseases. Medeia’s discovery platforms are centered on the expertise of Medeia’s scientific founders in the field of molecular medicine and include programs based on both small molecule and cell therapy approaches. Medeia has partnered its lead small molecule program with Orion Corporation.

www.medeiatherapeutics.com

 

portfolio

Onbone Oy

Onbone (ex Injectobone) is a Finnish medtech company established in 2008. Onbone’s business idea is to develop and manufacture innovative medical devices for orthopedics and traumatology. The company has two product lines under development: biodegradable bone cement, BIOCEMENT™ and reshapable, ecological cast product, OMNICAST™. Both product lines are based on Onbone’s proprietary biomaterial inventions.


www.onbone.com

 

portfolio

miacom Diagnostics GmbH

miacom is a German diagnostic company developing kits for the rapid identification of pathogens from stool, sputum and blood samples. miacom’s technology is based on a proprietary advancement of the FISH technology. miacom's technology offers a simple, affordable and fast alternative to the current culture or PCR-based products.


www.miacom-diagnostic.com